Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity
Saved in:
| Published in: | Endocrinology, Diabetes & Metabolism Case Reports |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity
- Sarcopenia and sarcopenic obesity in type 2 diabetes mellitus and cardiovascular disease: current perspective and narrative review
- Cystatin C and Its Role in Patients with Type 1 and Type 2 Diabetes Mellitus
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials
- Thyroid Diseases in Omani Type 2 Diabetics: A Retrospective Cross-Sectional Study
- Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes
- Insights from maturity-onset diabetes of the young into impaired insulin secretion in type 2 diabetes